Izotropic Corporation Logo

Izotropic Corporation

IZOZF

(1.8)
Stock Price

0,06 USD

-455.3% ROA

155.87% ROE

-1.74x PER

Market Cap.

10.226.643,79 USD

-137.81% DER

0% Yield

0% NPM

Izotropic Corporation Stock Analysis

Izotropic Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Izotropic Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (320.9%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-4.43x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-107%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 ROA

The stock's ROA (-547.91%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Izotropic Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Izotropic Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Izotropic Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Izotropic Corporation Revenue
Year Revenue Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Izotropic Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 793.036 100%
2022 3.411.903 76.76%
2023 3.085.488 -10.58%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Izotropic Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 72.688
2018 560.442 87.03%
2019 391.997 -42.97%
2020 1.088.708 63.99%
2021 3.903.267 72.11%
2022 3.163.870 -23.37%
2023 1.584.016 -99.74%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Izotropic Corporation EBITDA
Year EBITDA Growth
2017 -72.688
2018 -700.867 89.63%
2019 -391.997 -78.79%
2020 -1.152.563 65.99%
2021 -4.974.496 76.83%
2022 -6.628.275 24.95%
2023 -5.160.968 -28.43%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Izotropic Corporation Gross Profit
Year Gross Profit Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Izotropic Corporation Net Profit
Year Net Profit Growth
2017 -98.319
2018 -730.129 86.53%
2019 -398.537 -83.2%
2020 -1.155.842 65.52%
2021 -4.976.126 76.77%
2022 -6.654.692 25.22%
2023 -5.542.080 -20.08%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Izotropic Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Izotropic Corporation Free Cashflow
Year Free Cashflow Growth
2017 -50.559
2018 -622.496 91.88%
2019 -442.614 -40.64%
2019 -442.614 0%
2020 -987.432 55.18%
2021 -3.105.637 68.21%
2022 -4.788.349 35.14%
2023 -816.130 -486.71%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Izotropic Corporation Operating Cashflow
Year Operating Cashflow Growth
2017 -50.559
2018 -604.879 91.64%
2019 -442.614 -36.66%
2019 -442.614 0%
2020 -987.432 55.18%
2021 -3.081.409 67.96%
2022 -4.764.121 35.32%
2023 -811.051 -487.4%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Izotropic Corporation Capital Expenditure
Year Capital Expenditure Growth
2017 0
2018 17.617 100%
2019 0 0%
2019 0 0%
2020 0 0%
2021 24.228 100%
2022 24.228 0%
2023 5.079 -377.02%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Izotropic Corporation Equity
Year Equity Growth
2017 -64.671
2018 407.763 115.86%
2019 316.843 -28.7%
2019 316.843 0%
2020 707.219 55.2%
2021 4.517.373 84.34%
2022 -374.589 1305.95%
2023 -1.511.820 75.22%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Izotropic Corporation Assets
Year Assets Growth
2017 149.688
2018 491.637 69.55%
2019 339.058 -45%
2019 339.058 0%
2020 777.211 56.38%
2021 4.686.655 83.42%
2022 2.269.035 -106.55%
2023 1.160.966 -95.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Izotropic Corporation Liabilities
Year Liabilities Growth
2017 214.359
2018 83.874 -155.57%
2019 22.215 -277.56%
2019 22.215 0%
2020 69.992 68.26%
2021 169.282 58.65%
2022 2.643.624 93.6%
2023 2.672.786 1.09%

Izotropic Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.11
Price to Earning Ratio
-1.74x
Price To Sales Ratio
0x
POCF Ratio
-1.86
PFCF Ratio
-2.06
Price to Book Ratio
-6.09
EV to Sales
0
EV Over EBITDA
-2.23
EV to Operating CashFlow
-2.3
EV to FreeCashFlow
-2.29
Earnings Yield
-0.57
FreeCashFlow Yield
-0.49
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.27
Graham NetNet
-0.04

Income Statement Metrics

Net Income per Share
-0.11
Income Quality
0.82
ROE
4.78
Return On Assets
-12.62
Return On Capital Employed
1.21
Net Income per EBT
1
EBT Per Ebit
1.1
Ebit per Revenue
0
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.1
Free CashFlow per Share
-0.1
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
-1.32
Return on Invested Capital
-8.03
Return on Tangible Assets
-4.55
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,02
Book Value per Share
-0,03
Tangible Book Value per Share
-0.03
Shareholders Equity per Share
-0.03
Interest Debt per Share
0.05
Debt to Equity
-1.38
Debt to Assets
1.79
Net Debt to EBITDA
-0.22
Current Ratio
0.43
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-1.38
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.2

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Izotropic Corporation Dividends
Year Dividends Growth

Izotropic Corporation Profile

About Izotropic Corporation

Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.

CEO
Mr. Robert Louis Thast
Employee
0
Address
800 – 15355 24th Avenue
Surrey, V4A 2H9

Izotropic Corporation Executives & BODs

Izotropic Corporation Executives & BODs
# Name Age
1 Ms. Jaclyn Thast
Operations Manager & Corporate Secretary
70
2 Mr. Robert Louis Thast
Founder, Interim Chief Executive Officer & Chairman
70
3 Mr. Ralph F. Proceviat CPA
Director & Interim Chief Financial Officer
70
4 Dr. Younes Achkire Ph.D.
Executive Vice President of Product Engineering & Chief Operating Officer
70
5 Mr. Ali Reza Sodagar
Legal Advisor & Independent Director
70

Izotropic Corporation Competitors